MGLL and early-onset autosomal dominant Alzheimer disease: ,27 Inhibition of MAGL (monoacylglycerol lipase – enzyme degrading endocannabinoid 2-arachidonyl glycerol) has been proposed as a potential therapeutic approach for treatment of diverse neurological and neurodegenerative diseases, such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and traumatic brain injury.28